We are live on
!
Find out more
Voloridge Investment Management Portfolio holdings
AUM
$25B
1-Year Est. Return
28.08%
This Fund
S&P 500
This Quarter
Est. Return
+7.29%
1 Year Est. Return
+28.08%
3 Year Est. Return
+85.2%
5 Year Est. Return
+73.43%
10 Year Est. Return
+582.16%
AUM
$21.2B
AUM Growth
+$1.07B
(+5.3%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
1.06%
Top 10 Holdings %
Top 10 Hldgs %
9.44%
Holding
1,639
New
311
Increased
467
Reduced
550
Closed
311
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$211M |
| 2 |
AbbVie
ABBV
|
+$176M |
| 3 |
Apple
AAPL
|
+$170M |
| 4 |
Nike
NKE
|
+$161M |
| 5 |
Coca-Cola
KO
|
+$141M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$221M |
| 2 |
Medtronic
MDT
|
+$163M |
| 3 |
UnitedHealth
UNH
|
+$148M |
| 4 |
Johnson & Johnson
JNJ
|
+$133M |
| 5 |
Pfizer
PFE
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.66% |
| 2 | Consumer Discretionary | 14.98% |
| 3 | Healthcare | 13.91% |
| 4 | Financials | 10.93% |
| 5 | Industrials | 10.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Amylyx Pharmaceuticals
AMLX
$2.5B
| $2.47M | 0.01% |
114,629
-20,836
| -15% | -$563K |
|
927
Ingredion
INGR
$6.63B
| $2.45M | 0.01% |
23,152
+503
| +2% | +$53.5K |
|
928
4D Molecular Therapeutics
FDMT
$609M
| $2.45M | 0.01% |
135,661
+23,563
| +21% | +$434K |
|
929
Martin Marietta Materials
MLM
$32.7B
| $2.44M | 0.01% |
5,278
-8,234
| -61% | -$3.25M |
|
930
US Foods
USFD
$23.8B
| $2.43M | 0.01% |
+55,154
| New | +$2.19M |
|
|
EDR
931
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $2.42M | 0.01% |
101,371
+43,077
| +74% | +$1.01M |
|
932
Stepan Co
SCL
$1.48B
| $2.41M | 0.01% |
25,226
-5,840
| -19% | -$555K |
|
933
Cardinal Health
CAH
$53.8B
| $2.38M | 0.01% |
+25,198
| New | +$2.13M |
|
934
Aaon
AAON
$7.23B
| $2.38M | 0.01% |
37,677
-65,090
| -63% | -$4.12M |
|
|
ARGO
935
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $2.38M | 0.01% |
80,327
+2,429
| +3% | +$71.5K |
|
|
SLCA
936
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $2.38M | 0.01% |
196,035
+103,900
| +113% | +$1.28M |
|
937
Alcoa
AA
$13.1B
| $2.37M | 0.01% |
+69,963
| New | +$2.54M |
|
938
Domo
DOMO
$187M
| $2.36M | 0.01% |
161,214
-103,256
| -39% | -$1.52M |
|
939
East-West Bancorp
EWBC
$18.6B
| $2.34M | 0.01% |
+44,278
| New | +$2.25M |
|
940
Northwest Natural Holdings
NWN
$2.14B
| $2.32M | 0.01% |
53,964
-14,930
| -22% | -$675K |
|
941
Genmab
GMAB
$19.3B
| $2.32M | 0.01% |
61,055
-121,772
| -67% | -$4.85M |
|
942
Arcos Dorados Holdings
ARCO
$1.71B
| $2.31M | 0.01% |
+225,345
| New | +$1.93M |
|
943
Pliant Therapeutics
PLRX
$66.9M
| $2.31M | 0.01% |
127,401
-40,392
| -24% | -$956K |
|
944
Protolabs
PRLB
$2.21B
| $2.29M | 0.01% |
65,575
-21,013
| -24% | -$669K |
|
945
ACM Research
ACMR
$5.65B
| $2.28M | 0.01% |
174,365
-112,437
| -39% | -$1.18M |
|
946
Collegium Pharmaceutical
COLL
$913M
| $2.28M | 0.01% |
105,963
-18,178
| -15% | -$413K |
|
947
Kornit Digital
KRNT
$827M
| $2.27M | 0.01% |
77,196
-93,406
| -55% | -$2.11M |
|
948
Lakeland Financial Corp
LKFN
$1.56B
| $2.26M | 0.01% |
46,481
-1
| -0% | -$52 |
|
|
SYNH
949
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $2.24M | 0.01% |
53,208
-365,102
| -87% | -$14.8M |
|
950
Nordson
NDSN
$17.3B
| $2.24M | 0.01% |
9,034
-28,944
| -76% | -$6.46M |
|
Similar funds
JG
OAG
WP
Voloridge Investment Management's Q2 2023 Portfolio in Review
As of Q2 2023, Voloridge Investment Management held 1,639 positions worth $21.2B, up 5.3% from $20.1B the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.
Voloridge Investment Management's Q2 2023 filing shows 311 new, 467 increased, 550 reduced and 311 closed positions. Its largest new stake was Berkshire Hathaway Class B: 646,010 shares worth $220M. The largest sale was Accenture, an estimated $221M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Voloridge Investment Management's largest Q2 2023 buy was Berkshire Hathaway Class B: 646,010 shares worth $220M.
- Voloridge Investment Management added most to Coca-Cola in Q2 2023, an estimated $141M increase.
- Voloridge Investment Management's biggest Q2 2023 reduction was Medtronic, cutting an estimated $163M.
- Voloridge Investment Management fully exited Accenture in Q2 2023, selling an estimated $221M.
- Voloridge Investment Management's ten largest holdings make up 9.4% of its $21.2B portfolio in Q2 2023.
- Voloridge Investment Management opened 311 new positions and closed 311 in Q2 2023.
- Voloridge Investment Management's portfolio value rose 5.3% quarter-over-quarter to $21.2B.
Based on Voloridge Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.